Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 63

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 63
---
 Shares that the holder has the right to acquire within 60 days of May 28, 2025 without such holder or any of such holder’s affiliates beneficially owning more than the beneficial ownership limitation of 9.99%. The address for Alpha is Lettstrasse 32, Vaduz 9490, Liechtenstein. Nicola Feuerstein, a Director of Alpha, holds voting and dispositive power over the securities held by Alpha. At the Closing, 81,994 RSUs issued by Kadimastem are expected to be exchanged for 376,296 RSUs of the combined company, and 175,600 Kadimastem options to purchase Kadimastem Ordinary Shares are expected to be exchanged for 492,357 options to purchase NLS Common Shares of the combined company. Q.What is the anticipated ownership of options, warrants and other outstanding equity awards that are anticipated to remain outstanding following the completion of the Merger? As of May 28, 2025, the expected total amount of RSUs of Kadimastem that will be exchanged for RSUs of NLS is 81,994 RSUs of Kadimastem, which will equal to 376,296 RSUs of NLS at the Effective Time. All such RSUs have been and shall continue to be owned by current and past officers and employees of Kadimastem, and represent approximately 1.11% of the estimated number of issued and outstanding shares of the combined company immediately following the Closing. As of May 28, 2025, the total amount of Kadimastem options that will be exchanged for NLS options at the Effective Time will be 175,600, which will be exchanged for 805,886 NLS options. All such options have been and shall continue to be owned by current and past officers and employees of Kadimastem, and represent approximately 2.04% of the estimated number of issued and outstanding shares of the combined company immediately following the Closing. Additionally, NLS is required to make payments under a finders agreement of warrants to purchase $500,000 worth of NLS Common Shares with an exercise price per share equal to the price per NLS Common Share on Nasdaq immediately prior to the public announcement of such transaction. For more information, please see “The Merger — NLS’s Background of the Merger.” Q.Who can help answer my questions? With regard to the NLS Meeting, shareholders of NLS who have questions may contact NLS